- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06702592
Sostegno e sopravvivenza dei laici al cancro del testicolo virtuale Obiettivo 2 (VITALSS)
Supporto e sopravvivenza per i laici virtuali nel cancro testicolare (studio VITALSS) Obiettivo 2
This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Deborah S Usinger
- Numero di telefono: 919-962-5431
- Email: dusinger@email.unc.edu
Backup dei contatti dello studio
- Nome: Taylor J Greene
- Numero di telefono: 919-962-5506
- Email: taylor_greene@med.unc.edu
Luoghi di studio
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Investigatore principale:
- Hung-Jui Tan, MD, MSHPM
-
Contatto:
- Deborah M Usinger
- Numero di telefono: 919-962-0000
- Email: dusinger@email.unc.edu
-
Contatto:
- Taylor L Greene
- Numero di telefono: (919) 962-0000
- Email: taylor_greene@med.unc.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men within 5 years of their initial diagnosis of germ cell testicular cancer.
- The subject is willing and able to comply with study procedures based on the judgment of the investigator.
- Adults aged 18-95 years old.
- Electronic informed consent was obtained to participate in the study.
Exclusion Criteria:
- Woman gender
- Non-English speaking
- Unwilling or unable to complete informed consent.
- On active treatment for another cancer.
- Actively receiving chemotherapy, radiation, or surgery for testicular cancer.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Virtual support
Participants will have access to the virtual support platform. |
Subjects will use a virtual support platform that was built for their needs. |
|
Altro: Patient educational material
Participants will have access to patient educational material only. |
Participants will have access to patient educational material. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Emotional well-being scores comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Emotional well-being will be assessed by patient-reported outcomes questionnaires using a 9-item Positive Affect and Well-Being assessment from the Neuro-QOL Item Bank v1. Emotional well-being scores in virtual support and enhanced usual care will be compared. It is a 5-point Likert scale, higher scores reflect better emotional well-being. |
At baseline, 3-months, and 6-months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Negative mental health comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Negative mental health will be assessed by patient-reported outcomes questionnaires using 17 PROMIS items for anxiety, depression, loneliness, and stress. Negative mental health scores in virtual support and enhanced usual care will be compared. Scoring: Each item is rated on a 5-point scale between never (1) to always (5). The responses for each item are summed to get a total raw score. T-Scores: The raw score is then converted to a T-score using a scoring table specific to the PROMIS Anxiety item bank. T-scores standardize the results, making them comparable across different populations and studies. A T-score has a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Social well-being, acceptance and inclusion comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Social well-being will be assessed by patient-reported outcomes questionnaires using the 6-item Acceptance/Inclusion subscale of the General Belongingness Scale (GBS). GBS measures an individual's sense of belonging and social connectedness. It consists of 12 items that assess feelings of acceptance and inclusion. Each item is rated on a 7-point Likert scale (1 = Strongly Disagree and 7 = Strongly Agree). Higher scores reflect better inclusion. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Financial Toxicity comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Financial Toxicity will be assessed by patient-reported outcomes questionnaires using a 12-item Comprehensive Score for Financial Toxicity (COST) instrument. Each item is rated on a 5-point Likert scale 0= = Not at all to 4= Very much. Higher scores indicate higher financial difficulties. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Self-efficacy comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Self-efficacy will be assessed by patient-reported outcomes questionnaires using 20 PROMIS items for self-efficacy for managing daily activities, emotions, social interactions, and symptoms. Self-efficacy scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point scale ( 1 = Never, 5 = Always). Responses are summed to get a total raw score for each domain. Raw scores are converted to T-scores using a scoring table. T-scores standardize results, with a mean of 50 and a standard deviation of 10 in the general population. |
At baseline, 3-months, and 6-months
|
|
Sexual Function and Satisfaction comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Sexual Function and Satisfaction will be assessed by patient-reported outcomes questionnaires using a 20-item PROMIS SexFS instrument with domains for interest in sexual activity, global satisfaction with sex life, orgasm, and erectile function. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale: 1 = Not at all to 5= Very much. Raw scores are converted to T-scores using a scoring table specific to the PROMIS Sexual Function and Satisfaction profile. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population.Higher T-scores indicate better sexual function and satisfaction. |
At baseline, 3-months, and 6-months
|
|
Functional well-being comparison Functional well-being comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
Functional well-being will be assessed by patient-reported outcomes questionnaires using a 7-item subscale of the Functional Assessment of Cancer Therapy (FACT-G) instrument. Each item is rated on a 5-point Likert scale, 0= = Not at all to 4= Very much. Higher scores indicate better well-being. Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
General Quality of Life comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
General Quality of Life will be assessed by patient-reported outcomes questionnaires using the PROMIS Global Health scale is an 8-item, validated survey that represents five core domains (physical function, pain, fatigue, emotional distress, social health). Two items each for physical and mental health as well as a question on quality of life will be administered. Scores in virtual support and enhanced usual care will be compared. Each item is rated on a 5-point Likert scale:1 = Poor to 5 = Excellent. Responses are summed to get a total raw score. The raw score is converted to a T-score using a scoring table. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate better overall health |
At baseline, 3-months, and 6-months
|
|
General Self-Efficacy comparison
Lasso di tempo: At baseline, 3-months, and 6-months
|
General Self-Efficacy will be assessed by patient-reported outcomes questionnaires using the 4-item PROMIS instrument that measures the respondent's belief in managing specific problems or issues. Each item is scored on a 5-point Likert scale, 1 = Never to 5 = Always. The raw score is then converted to a T-score using a scoring table specific to the PROMIS domain being measured. T-scores standardize the results, with a mean of 50 and a standard deviation of 10 in the general population. Higher T-scores indicate more of the concept being measured Scores in virtual support and enhanced usual care will be compared. |
At baseline, 3-months, and 6-months
|
|
Virtual platform usage
Lasso di tempo: At baseline, 3-months, and 6-months
|
Virtual platform usage will be assessed by time, visits, scrolling, posts, and messages spent on the virtual platform. |
At baseline, 3-months, and 6-months
|
|
Healthcare and supportive care utilization
Lasso di tempo: At baseline, 3-months, and 6-months
|
Self-reported use of healthcare and supportive care services will be assessed by a survey. Participants will be asked to quantify healthcare or other supportive care visits over the intervention period. |
At baseline, 3-months, and 6-months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Hung-Jui Tan, MD, UNC Lineberger Comprehensive Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie genitali, maschio
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie genitali, maschio
- Malattie urogenitali maschili
- Sintomi comportamentali
- Neoplasie delle ghiandole endocrine
- Disturbi gonadici
- Stress, Psicologico
- Malattie testicolari
- Comportamento
- Stress finanziario
- Neoplasie testicolari
Altri numeri di identificazione dello studio
- LCCC2418 AIM2
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .